Rong Fu

List of Publications by Year
in descending order

166 papers	1,012 citations	687220 13 h-index	677027 22 g-index
185 all docs	185 docs citations	185 times ranked	1355 citing authors

#	Article	IF	Citations
1	Research Progress on NK Cell Receptors and Their Signaling Pathways. Mediators of Inflammation, 2020, 2020, 1-14.	1.4	48
2	CD8⁺ T cells exhaustion induced by myeloidâ€derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Galâ€9 pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 1046-1058.	1.6	43
3	A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomedicine and Pharmacotherapy, 2016, 83, 1032-1037.	2.5	38
4	Multiple Myeloma-Derived Exosomes Inhibit Osteoblastic Differentiation and Improve IL-6 Secretion of BMSCs from Multiple Myeloma. Journal of Investigative Medicine, 2020, 68, 45-51.	0.7	37
5	Current research status of HLA in immuneâ€related diseases. Immunity, Inflammation and Disease, 2021, 9, 340-350.	1.3	35
6	Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. Frontiers in Oncology, 2020, 10, 1595.	1.3	33
7	Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell International, 2014, 14, 132.	1.8	31
8	Abnormal quantity and function of regulatory T cells in peripheral blood of patients with severe aplastic anemia. Cellular Immunology, 2015, 296, 95-105.	1.4	30
9	CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease. International Journal of Oncology, 2017, 50, 631-639.	1.4	26
10	Elevated TIM3+ hematopoietic stem cells in untreated myelodysplastic syndrome displayed aberrant differentiation, overproliferation and decreased apoptosis. Leukemia Research, 2014, 38, 714-721.	0.4	21
11	Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway. Leukemia and Lymphoma, 2021, 62, 218-223.	0.6	19
12	Downregulation of Pim-2 induces cell cycle arrest in the G0/G1 phase via the p53-non-dependent p21 signaling pathway. Oncology Letters, 2018, 15, 4079-4086.	0.8	17
13	Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes. International Journal of Hematology, 2017, 106, 248-257.	0.7	16
14	NK cells suppress CD8+ T cell immunity via NKG2D in severe aplastic anemia. Cellular Immunology, 2019, 335, 6-14.	1.4	16
15	Abnormal histone acetylation of CD8+ T cells in patients with severe aplastic anemia. International Journal of Hematology, 2016, 104, 540-547.	0.7	14
16	PKM2 Is Required to Activate Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-9.	1.9	14
17	Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. Journal of Clinical Laboratory Analysis, 2020, 34, e23008.	0.9	14
18	Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clinical and Experimental Immunology, 2021, 205, 53-62.	1.1	14

#	Article	IF	Citations
19	Role and Function of T Cell-Derived Exosomes and Their Therapeutic Value. Mediators of Inflammation, 2021, 2021, 1-7.	1.4	14
20	Erythroblastic Islands in the Bone Marrow of Patients with Immune-Related Pancytopenia. PLoS ONE, 2014, 9, e95143.	1.1	12
21	Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. Oncology Letters, 2016, 11, 2347-2352.	0.8	12
22	Paraneoplastic <scp>E</scp>vans syndrome in a patient with adenocarcinoma of the lung: <scp>A</scp> case report. Thoracic Cancer, 2017, 8, 57-60.	0.8	12
23	<scp>TIM3</scp>/<scp>CEACAM1</scp> pathway involves in myeloidâ€derived suppressor cells induced <scp>CD8</scp>⁺ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome. Immunology, 2023, 168, 273-289.	2.0	12
24	Decreased TIM-3 expression of peripheral blood natural killer cells in patients with severe aplastic anemia. Cellular Immunology, 2017, 318, 17-22.	1.4	11
25	Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes. Leukemia Research, 2018, 67, 12-16.	0.4	11
26	Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes. Oncology Letters, 2018, 15, 5497-5504.	0.8	11
27	The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. Hematology, 2018, 23, 639-645.	0.7	11
28	Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function. Journal of Clinical Laboratory Analysis, 2019, 33, e22888.	0.9	11
29	CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3 Î² /cyclinD1 signal pathway in Myeloma Bone Disease. Cancer Medicine, 2020, 9, 737-744.	1.3	11
30	IgG autoantibody subclasses altered in immuno-related hemocytopenia. Cellular Immunology, 2015, 294, 13-20.	1.4	10
31	The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 216-226.	0.3	10
32	Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. Journal of Investigative Medicine, 2019, 67, 39-47.	0.7	10
33	Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis. Journal of Investigative Medicine, 2019, 67, 1067-1075.	0.7	9
34	Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-ÎºB Signal Pathways. Frontiers in Oncology, 2020, 10, 584530.	1.3	9
35	Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes. Innate Immunity, 2020, 26, 703-715.	1.1	9
36	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from Higher-Risk MDS Patients by Regulating the ROS-Related Wnt/Î²-Catenin Pathway. Stem Cells International, 2020, 2020, 1-16.	1.2	9

#	Article	IF	Citations
37	CTLAâ€4 and HLAâ€DQ are key molecules in the regulation of mDCâ€mediated cellular immunity by Tregs in severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2020, 34, e23443.	0.9	9
38	Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. International Journal of Molecular Medicine, 2020, 45, 1112-1120.	1.8	9
39	Involvement of MM cellâ€derived exosomes in T lymphocytes immune responses. Oncology Letters, 2020, 20, 31.	0.8	9
40	A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults. International Journal of Hematology, 2016, 104, 462-467.	0.7	8
41	The shortening telomere length of T lymphocytes maybe associated with hyperâ€function in servere aplastic anemia. Molecular Medicine Reports, 2018, 17, 1015-1021.	1.1	8
42	Screening novel autoantigens targeted by serum IgG autoantibodies in immunorelated pancytopenia by SEREX. International Journal of Hematology, 2017, 106, 622-630.	0.7	8
43	Lower level of ILâ€35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs testâ€positive hemocytopenia. Molecular Medicine Reports, 2017, 17, 2973-2981.	1.1	8
44	Abnormal expression and mutation of the RBPJ gene may be involved in CD59â€‘ clonal proliferation in paroxysmal nocturnal hemoglobinuria. Experimental and Therapeutic Medicine, 2019, 17, 4536-4546.	0.8	8
45	Bone Marrow Plasma Cytokine Signature Profiles in Severe Aplastic Anemia. BioMed Research International, 2020, 2020, 1-11.	0.9	8
46	Treatment and outcome patterns of patients with WaldenstrÃ¶mâ€™s macroglobulinemia: a large, multicenter retrospective review in China. Leukemia and Lymphoma, 2021, 62, 2657-2664.	0.6	8
47	Preliminary Study of the Relationship Between EPO Receptor and Autoantibody on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coomb's Test(+) Hemocytopenia. Blood, 2010, 116, 4436-4436.	0.6	8
48	TRAIL in CD8+ T cells from patients with severe aplastic anemia. International Journal of Hematology, 2017, 106, 490-499.	0.7	7
49	Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia. Journal of Clinical Laboratory Analysis, 2021, 35, e23922.	0.9	7
50	Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age and Ageing, 2022, 51, .	0.7	7
51	Tumorâ€associated macrophages regulate the function of cytotoxic T lymphocyte through <scp>PD</scp>â€1/<scp>PDâ€L1</scp> pathway in multiple myeloma. Cancer Medicine, 2022, 11, 4838-4848.	1.3	7
52	Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease. Annals of Hematology, 2016, 95, 1099-1106.	0.8	6
53	Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2017, 92, E51-E53.	2.0	6
54	Transforming growth factor 15 increased in severe aplastic anemia patients. Hematology, 2017, 22, 548-553.	0.7	6

#	Article	IF	Citations
55	De-escalation empirical antibiotic therapy improved survival for patients with severe aplastic anemia treated with antithymocyte globulin. Medicine (United States), 2017, 96, e5905.	0.4	6
56	Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Clinical Drug Investigation, 2017, 37, 167-174.	1.1	6
57	The short-term effect of histone deacetylaseï¿½inhibitors, chidamide and valproic acid, onï¿½theï¿½NFâ€ºBï¿½pathway in multiple myeloma cells. International Journal of Molecular Medicine, 2019, 43, 285-293.	1.8	6
58	Gene mutations associated with thrombosis detected by wholeâ€exome sequencing in paroxysmal nocturnal hemoglobinuria. International Journal of Laboratory Hematology, 2019, 41, 424-432.	0.7	6
59	Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome. Journal of Investigative Medicine, 2019, 67, 1125-1130.	0.7	6
60	Effects of Shikonin on the Functions of Myeloid Dendritic Cells in a Mouse Model of Severe Aplastic Anemia. Mediators of Inflammation, 2020, 2020, 1-10.	1.4	6
61	The dysfunction of platelets in paroxysmal nocturnal hemoglobinuria. Thrombosis Research, 2016, 148, 50-55.	0.8	5
62	Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma. International Journal of Clinical Oncology, 2017, 22, 585-592.	1.0	5
63	High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. Annals of Hematology, 2017, 96, 331-333.	0.8	5
64	The Risk of Clonal Evolution of Granulocyte Colony-Stimulating Factor for Acquired Aplastic Anemia: A Systematic Review and Meta-Analysis. Acta Haematologica, 2018, 140, 141-145.	0.7	5
65	Epstein Barr Virus Infection Affects Function of Cytotoxic T Lymphocytes in Patients with Severe Aplastic Anemia. BioMed Research International, 2018, 2018, 1-10.	0.9	5
66	Proteomics analysis reveals alterations of NK cells in patients with severe aplastic anemia. International Journal of Laboratory Hematology, 2020, 42, 308-315.	0.7	5
67	Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 949-954.	1.3	5
68	Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia. Cellular Immunology, 2021, 364, 104343.	1.4	5
69	Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia. Frontiers in Immunology, 2021, 12, 631954.	2.2	5
70	Plasma Metabolomic and Intestinal Microbial Analyses of Patients With Severe Aplastic Anemia. Frontiers in Cell and Developmental Biology, 2021, 9, 669887.	1.8	5
71	Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma. Cancer Biology and Medicine, 2021, 18, 721-733.	1.4	5
72	Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immuneâ€related pancytopenia. Molecular Medicine Reports, 2020, 22, 2012-2020.	1.1	5

#	Article	IF	Citations
73	Role of B lymphocyte and its subpopulations in pathogenesis of immunorelated pancytopenia. Chinese Medical Sciences Journal, 2007, 22, 199-202.	0.2	5
74	Hodgkin's lymphoma associated with myelofibrosis: A case report. Oncology Letters, 2015, 10, 1551-1554.	0.8	4
75	High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1â€Î± signaling pathway. Oncology Letters, 2019, 17, 5395-5402.	0.8	4
76	Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis. Journal of Clinical Laboratory Analysis, 2020, 34, e23057.	0.9	4
77	Infection risk in autoimmune hematological disorders with lowâ€dose rituximab treatment. Journal of Clinical Laboratory Analysis, 2020, 34, e23455.	0.9	4
78	Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China . Cancer Management and Research, 2020, Volume 12, 8935-8941.	0.9	4
79	Th9 Cells in Peripheral Blood Increased in Patients with Immune-Related Pancytopenia. Journal of Immunology Research, 2020, 2020, 1-8.	0.9	4
80	Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2021, 35, e23667.	0.9	4
81	Upregulated expression of leukocyte immunoglobulinâ€like receptorÂA3 in patients with severe aplastic anemia. Experimental and Therapeutic Medicine, 2021, 21, 346.	0.8	4
82	Role of EZH2 in Bone Marrow Mesenchymal Stem Cells and Immuneâ€“Cancer Interactions. Critical Reviews in Oncology/Hematology, 2021, 169, 103547.	2.0	4
83	Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia. Journal of Clinical Laboratory Analysis, 2022, 36, e24339.	0.9	4
84	CD56^{bright} natural killer cells exhibit abnormal phenotype and function in severe aplastic anemia. International Journal of Laboratory Hematology, 2019, 41, 353-363.	0.7	3
85	Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma. Cytometry Part B - Clinical Cytometry, 2022, 102, 44-49.	0.7	3
86	lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	3
87	Availability of NK cell expansion agent combined with recombinant ILâ€2 and ILâ€15 stimulation on the expansion and highâ€purity of NK cells in patients with immuneâ€related pancytopenia inï¿½vitro. Molecular Medicine Reports, 2019, 20, 4358-4366.	1.1	3
88	A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis. Experimental Hematology and Oncology, 2022, 11, 1.	2.0	3
89	Expression and function of hematopoiesis-stimulating factor receptors on the GPIâ^' and GPI+ hematopoietic stem cells of patients with paroxysmal nocturnal hemoglobinuria/aplastic anemia syndrome. Experimental and Therapeutic Medicine, 2016, 11, 1668-1672.	0.8	2
90	Abnormal changes in the quantity and function of osteoblasts cultured inï¿½vitro in patients with myelodysplastic syndrome. Oncology Letters, 2018, 16, 4384-4390.	0.8	2

#	Article	IF	Citations
91	Effects of Epstein-Barr Virus Infection on CD19+ B Lymphocytes in Patients with Immunorelated Pancytopenia. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	2
92	The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia. Blood, 2019, 134, 3747-3747.	0.6	2
93	CD8+HLA-DR+ T Cells Are Increased in Patients with Severe Aplastic Anemia. Blood, 2012, 120, 4395-4395.	0.6	2
94	Abnormal numbers of CD4+ T lymphocytes and abnormal expression of CD4+ T lymphocyteâ€'secreted cytokines in patients with immuneâ€'related haemocytopenia. Molecular Medicine Reports, 2019, 20, 3979-3990.	1.1	2
95	Single wholeâ€genome sequencing analysis of metastatic biopsy is sufficient for investigational treatment opportunities in cancer. Cancer Communications, 2021, , .	3.7	2
96	Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China. Hematology, 2021, 26, 874-880.	0.7	2
97	SUZ12 participates in the proliferation of PNH clones by regulating histone H3K27me3 levels. Journal of Leukocyte Biology, 2022, 112, 243-255.	1.5	2
98	Clinical observation of lowâ€dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A singleâ€center retrospective analysis. Journal of Clinical Laboratory Analysis, 2022, 36, e24239.	0.9	2
99	Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease. Journal of Investigative Medicine, 2022, , jim-2021-002192.	0.7	2
100	Identification of potential pathogenic genes for severe aplastic anemia by wholeâ€exome sequencing. Journal of Clinical Laboratory Analysis, 2022, 36, e24438.	0.9	2
101	Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	1.9	2
102	Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. Experimental and Therapeutic Medicine, 2017, 15, 2525-2532.	0.8	1
103	Expression of C1q in the serum of patients with nonâ€'severe aplastic anemia, and its association with disease severity. Molecular Medicine Reports, 2019, 19, 1194-1202.	1.1	1
104	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Journal of Immunology Research, 2020, 2020, 1-10.	0.9	1
105	Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With Myelodysplastic Syndromes. Frontiers in Oncology, 2020, 10, 962.	1.3	1
106	The Role of lncRNA AF117829.1 in the Immunological Pathogenesis of Severe Aplastic Anaemia. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-19.	1.9	1
107	Iron Overload Impairs Bone Marrow Mesenchymal Stromal Cells from MDS Patients and Promotes Leukemia Transformation. Blood, 2019, 134, 5398-5398.	0.6	1
108	The Expression and Clinical Significance of PRAME Gene in Acute Leukemia.. Blood, 2007, 110, 4225-4225.	0.6	1

#	Article	IF	Citations
109	Study on the Dendritic Cell Subsets and Their Relationship with the Expressions of T-Bet and GATA-3 in Peripheral Lymphocytes of Severe Aplastic Anemia Patients. Blood, 2008, 112, 4901-4901.	0.6	1
110	Study of the Quantity and Function of Regulatory T Cells In the Hemocytopenic Patients with Positive BMMNC-Coombs Test. Blood, 2010, 116, 4875-4875.	0.6	1
111	TET2 Gene Expression in Bone Marrow Cells in Myelodysplastic Syndromes Patients and the Effect of Silencing TET2 by siRNA On Biological Characteristics of Healthy CD34+ Cells. Blood, 2012, 120, 4934-4934.	0.6	1
112	Increased Population Of Myeloid-Derived Suppressor Cells In Patients With Myelodysplastic Syndromes Overexpress ARG1 and Mediate CD8+ T Cell Inhibition. Blood, 2013, 122, 5212-5212.	0.6	1
113	Zoledronic Acid Inhibits Cell Growth of Multiple Myeloma Cells and Shows Synergistic Antimyeloma Effects with Bortezomib Via CD38 /cADPR /Ca2+ /Ras /Pakt /NF-Kb /Pim-2 Pathway. Blood, 2015, 126, 5311-5311.	0.6	1
114	The Role of PKM2 in the Activation of Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Blood, 2016, 128, 1497-1497.	0.6	1
115	Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study. Blood, 2019, 134, 5493-5493.	0.6	1
116	Pyruvate Kinase M2 Regulates Hif-1alpha Activity in Myeloid Dendritic Cells from Patients with Severe Aplastic Anemia. Blood, 2021, 138, 1109-1109.	0.6	1
117	BMSCs Regulate the Function of NK Cell By CD155/Tigit/CD226 Pathway in MDS Patients. Blood, 2021, 138, 4651-4651.	0.6	1
118	New Trends of Nontransplant therapy for Acquired Aplastic Anemia. Current Pharmaceutical Design, 2022, 28, .	0.9	1
119	Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation. Investigational New Drugs, 2022, 40, 738-746.	1.2	1
120	Pseudo-monoclonal gammopathy due to autoimmune disease: a case report. Journal of International Medical Research, 2020, 48, 030006051986661.	0.4	0
121	Long Non-coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients. Turkish Journal of Haematology, 2021, 38, 236-238.	0.2	0
122	The Auto-Antibodies on Bone Marrow Cells in the Patients with Systemic Lupus Erythematosus.. Blood, 2006, 108, 3856-3856.	0.6	0
123	Proliferative Function of Bone Marrow Hematopoietic Stem Cells of Patients with Systemic Lupus Erythematosus.. Blood, 2006, 108, 3857-3857.	0.6	0
124	An Analysis of Occurrence and Prognosis Related Factors of Renal Dysfunction in Patients with Multiple Myeloma.. Blood, 2007, 110, 4732-4732.	0.6	0
125	Study on the Ratio and Function of Macrophages in the Patients with BMMNCCoombs Test(+) Hematocytopenia. Blood, 2008, 112, 4656-4656.	0.6	0
126	In Vitro Study of the Function of Dendritic Cells on Stimulating T Lymphocytes Proliferation in Severe Aplastic Anemia. Blood, 2008, 112, 4919-4919.	0.6	0

#	Article	IF	Citations
127	Study on the Mechanism of â€˜eiâ€™formation in the Bone Marrow Smears of the Patients with BMMNC-Coombs Test(+) Hematocytopenia. Blood, 2008, 112, 4753-4753.	0.6	0
128	Expression of CD123 and CD114 on the Bone Marrow Cells of Patients with Myelodysplastic Syndromes. Blood, 2010, 116, 4966-4966.	0.6	0
129	Expression of dlk1 in the Bone Marrow Cells of Patients with Myelodysplastic Syndrome and Its Clinical Significance. Blood, 2011, 118, 5042-5042.	0.6	0
130	Preliminary Study of the Autoantigens on the Membrane of Erythropoietic Cells of the Patients with BMMNC- Coombâ€™s Test(+) Hemocytopenia. Blood, 2011, 118, 4382-4382.	0.6	0
131	The Somatic Mutation of PIG-A Gene and the Expressions of EGR-1 and WT1 Genes in Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2011, 118, 4379-4379.	0.6	0
132	Chemotherapy Plus Hematopoietic Growth Factor for Refractory Paroxysmal Nocturnal Hemoglobinuria: Diminishing PNH Clone and Stimulating Hematopoisis. Blood, 2011, 118, 4376-4376.	0.6	0
133	Study on the Pathways to Damage Hematopoiesis by CD8+ Effector T Cells of the Patients with Severe Aplastic Anemia. Blood, 2011, 118, 4371-4371.	0.6	0
134	TET2 mRNA Expression in Bone Marrow Mononuclear Cells of the Patients with Myelodysplastic Syndromes and it's Clinical Significances. Blood, 2011, 118, 5036-5036.	0.6	0
135	Study on the Quantities and Functions of Natural Killer Cell Subsets in Peripheral Blood of the Patients with Severe Aplastic Anemia,. Blood, 2011, 118, 3423-3423.	0.6	0
136	The Expressions of CD114, CD117 and STAT5 in CD34+CD59â^' and CD34+CD59+ Bone Marrow Cells of the Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2012, 120, 4404-4404.	0.6	0
137	Expression and Clinical Significance of Notch1 On the Membrane of Bone Marrow CD38+CD138+Plasma Cells in the Patients with Multiple Myeloma. Blood, 2012, 120, 4981-4981.	0.6	0
138	The Study Of The Effect and Mechanism Of Chemotherapy Plus Granulocyte Colony Stimulating Factor (DAG) for Refractory Paroxysmal Nocturnal Hemoglobinuria In Vitro. Blood, 2013, 122, 4717-4717.	0.6	0
139	Abnormal Expression Of Shelterin Is Associated With Short Telomere and Immune Disorder In Severe Aplastic Anemia. Blood, 2013, 122, 5562-5562.	0.6	0
140	The Mechanisms Of Damage To Bone Marrow By Iron Overload In Patients With Immuno-Related Pancytopenia. Blood, 2013, 122, 5561-5561.	0.6	0
141	Vitro Culture and Regulation Of Osteoblasts and Cellular Immunity Function In Multiple Myeloma patients. Blood, 2013, 122, 5329-5329.	0.6	0
142	Recombinant Human Thrombopoietin Promotes The Recovery Of Megakaryocyte Lineage In Patients With Severe Aplastic Anemia Receiving Immunosuppressive Therapy. Blood, 2013, 122, 2437-2437.	0.6	0
143	Decreased Tim-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2015, 126, 4767-4767.	0.6	0
144	Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia. Blood, 2015, 126, 4765-4765.	0.6	0

#	Article	IF	Citations
145	Decreased TIM-3 Expression Level of Peripheral Blood Natural Killer Cells in Severe Aplastic Anemia. Blood, 2016, 128, 5078-5078.	0.6	0
146	MM-derived exosomes can promote apoptosis and inhibit proliferation of HD-CD4+T, inhibit apoptosis and promote proliferation but inhibit perforin secretion of HD-CD8+T, inhibit apoptosis and promote proliferation HD-Treg, and promotes IL-10 secretion. Blood, 2018, 132, 5602-5602.	0.6	0
147	Study of TIM-3 in Pathogenesis of Myelodysplastic Syndrome. Blood, 2018, 132, 4388-4388.	0.6	0
148	The Effect of Pyruvate Kinase M2: Inhibitor(shikonin) on the Function of Mdc in Severe Aplastic Anemia Mouse Model. Blood, 2019, 134, 5021-5021.	0.6	0
149	Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma. Blood, 2019, 134, 5521-5521.	0.6	0
150	Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma. Blood, 2019, 134, 4416-4416.	0.6	0
151	The Study of Proliferation Relative Long Non-Coding RNA in CD59- Cell from Paroxysmalnocturnal Hemoglobinuria Patients. Blood, 2019, 134, 5023-5023.	0.6	0
152	Trial in Progress: A Perspective Study of Pan-Oral Triplet Regimen Pomalidomide, Ixazomib and Dexamethasone in Relapsed or Refractory Myeloma Patients. Blood, 2021, 138, 4783-4783.	0.6	0
153	Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China. Blood, 2021, 138, 4728-4728.	0.6	0
154	Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China. Blood, 2021, 138, 4766-4766.	0.6	0
155	The Role of TLR4 Inducing Macrophage Pyroptosis in the Pathogenesis of Severe Aplastic Anemia. Blood, 2021, 138, 1114-1114.	0.6	0
156	SUZ12 Participates in PNH Cloning Proliferation By Regulating Histone H3K27me3 Methylation Level. Blood, 2021, 138, 1106-1106.	0.6	0
157	Study of Bone Marrow Mesenchymal Stem Cells Regulating NK Cells Function through Tigit/ CD226 in Patients with Multiple Myeloma. Blood, 2021, 138, 2685-2685.	0.6	0
158	Bone Marrow-Derived Mesenchymal Stem Cells Inhibit CD8+ t Cell Immune Responses Via PD-1/PD-L1 Pathway in Multiple Myeloma. Blood, 2020, 136, 53-54.	0.6	0
159	WaldenstrÃ¶m's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals. Blood, 2020, 136, 5-6.	0.6	0
160	Sequential Intravenous to Oral Proteasome Inhibitor Based Regimens for the Treatment of Newly Diagnosed Multiple Myeloma Patients: A Real-World Study. Blood, 2020, 136, 38-39.	0.6	0
161	The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Blood, 2020, 136, 10-11.	0.6	0
162	The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59- cell from Paroxysmal Nocturnal Hemoglobinuria Patients. Blood, 2020, 136, 33-34.	0.6	0

#	Article	IF	Citations
163	Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivationâ€“related apoptosis. Journal of Investigative Medicine, 2021, , jim-2021-002147.	0.7	0
164	Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia. Disease Markers, 2022, 2022, 1-10.	0.6	0
165	Ferritin Light Chain: A Candidate Autoantigen in Immuno-Related Pancytopenia. Frontiers in Immunology, 2022, 13, 851096.	2.2	0
166	Gene therapy with Bâ€cell maturation antigen/ <scp>CD3</scp> bispecific antibody encoding plasmid <scp>DNA</scp> for treating multiple myeloma. British Journal of Haematology, 0, , .	1.2	0